Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
APLT Stock Summary
Top 10 Correlated ETFs
APLT
In the News

3 Penny Stocks To Buy According To Insiders In December
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulting in decreased physical activity NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes, at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.

Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)
Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galactosemia ph3 trial, APLT still plans for NDA submission. The pre-NDA meeting with the FDA this summer will be a big catalyst if positive. I expect a positive outcome from the meeting considering consistent and meaningful clinical benefit in multiple endpoints, orphan and fast-track designation, no alternative treatments, and the significant burden for affected patients.

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple presentations on AT-001 (caficrestat) and the ARISE-HF Phase 3 study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association to take place June 23 - 26 in San Diego, California.

7 Hot Growth Stocks Poised to Triple in 2023
Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear.

4 Top Penny Stocks To Buy According To Analysts, Targets Up To 695%
Analysts say these could be penny stocks to buy. Do you agree with their outlook?

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%
Analysts say these are penny stocks to buy but do you agree? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:10 p.m. ET in Boston.

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virtually at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 2:20 p.m. ET.

7 Top Penny Stocks To Watch With Big News This Week
Hot penny stocks to watch with news this week. The post 7 Top Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
APLT Financial details
APLT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.8 | -3.54 | -4.23 | -4.09 | -2.16 | |
Operating cash flow per share | -1.22 | -2.83 | -3.56 | -3.54 | -2.06 | |
Free cash flow per share | -1.22 | -2.83 | -3.56 | -3.54 | -2.06 | |
Cash per share | 2.05 | 3.03 | 4.41 | 3.16 | 0.81 | |
Book value per share | 1.73 | 2.54 | 3.73 | 2.44 | 0.11 | |
Tangible book value per share | 1.73 | 2.54 | 3.73 | 2.44 | 0.11 | |
Share holders equity per share | 1.73 | 2.54 | 3.73 | 2.44 | 0.11 | |
Interest debt per share | 0 | 0.17 | 0.1 | 0.07 | 0.01 | |
Market cap | 86.13M | 350.04M | 483.48M | 229.1M | 28.75M | |
Enterprise value | 67.39M | 333.22M | 427.75M | 176.55M | 12.98M | |
P/E ratio | -5.21 | -7.71 | -5.2 | -2.19 | -0.35 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -7.7 | -9.64 | -6.18 | -2.53 | -0.37 | |
PFCF ratio | -7.7 | -9.64 | -6.18 | -2.53 | -0.37 | |
P/B Ratio | 5.45 | 10.73 | 5.9 | 3.66 | 7.08 | |
PTB ratio | 5.45 | 10.73 | 5.9 | 3.66 | 7.08 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -5.07 | -7.31 | -4.53 | -1.67 | -0.16 | |
EV to operating cash flow | -6.03 | -9.18 | -5.47 | -1.95 | -0.17 | |
EV to free cash flow | -6.03 | -9.18 | -5.47 | -1.95 | -0.17 | |
Earnings yield | -0.19 | -0.13 | -0.19 | -0.46 | -2.84 | |
Free cash flow yield | -0.13 | -0.1 | -0.16 | -0.4 | -2.72 | |
Debt to equity | 0 | 0.06 | 0.02 | 0.02 | 0.22 | |
Debt to assets | 0 | 0.04 | 0.02 | 0.01 | 0.02 | |
Net debt to EBITDA | 1.41 | 0.37 | 0.59 | 0.5 | 0.19 | |
Current ratio | 4.57 | 3.27 | 4.83 | 3.34 | 1.12 | |
Interest coverage | 0 | -490.13 | -168.99 | -190.3 | 187.67 | |
Income quality | 0.68 | 0.8 | 0.83 | 0.86 | 0.95 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.37 | 14.22 | 18.85 | 14.99 | 2.28 | |
ROIC | -1.11 | -1.24 | -1.09 | -1.6 | -14.06 | |
Return on tangible assets | -0.82 | -0.94 | -0.89 | -1.16 | -2.13 | |
Graham Net | 1.56 | 1.8 | 3.39 | 2.09 | -0.1 | |
Working capital | 15.82M | 32.06M | 81.36M | 61.93M | 3.88M | |
Tangible asset value | 15.82M | 32.61M | 81.94M | 62.54M | 4.06M | |
Net current asset value | 15.82M | 30.37M | 80.03M | 61.04M | 3.01M | |
Invested capital | 0 | 0.06 | 0.02 | 0.02 | 0.22 | |
Average receivables | 0 | 0 | 252.5K | 515K | 400K | |
Average payables | 1.86M | 5.9M | 4.72M | 5.05M | 7M | |
Average inventory | 0 | 0 | -252.5K | -515K | -400K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.04 | -1.39 | -1.14 | -1.67 | -20.12 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.19 | 0 | 0 | |
Net income per share | -0.39 | -0.15 | -0.17 | -0.37 | -0.47 | |
Operating cash flow per share | -0.4 | -0.42 | -0.12 | -0.21 | -0.16 | |
Free cash flow per share | -0.4 | -0.42 | -0.12 | -0.21 | -0.16 | |
Cash per share | 0.99 | 0.81 | 0.41 | 0.45 | 0.41 | |
Book value per share | 0.2 | 0.11 | -0.07 | -0.05 | -0.12 | |
Tangible book value per share | 0.2 | 0.11 | -0.07 | -0.05 | -0.12 | |
Share holders equity per share | 0.2 | 0.11 | -0.07 | -0.05 | -0.12 | |
Interest debt per share | 0.05 | 0.05 | 0 | 0.02 | 0.01 | |
Market cap | 44.64M | 28.75M | 45.71M | 101.17M | 225.77M | |
Enterprise value | 6.82M | 14.07M | 23.57M | 67.45M | 189.62M | |
P/E ratio | -0.59 | -1.24 | -1.21 | -0.86 | -1.33 | |
Price to sales ratio | 0 | 0 | 4.29 | 0 | 0 | |
POCF ratio | -2.3 | -1.81 | -6.54 | -6.15 | -15.33 | |
PFCF ratio | -2.3 | -1.81 | -6.54 | -6.15 | -15.33 | |
P/B Ratio | 4.64 | 7.08 | -11.23 | -23.34 | -20.44 | |
PTB ratio | 4.64 | 7.08 | -11.23 | -23.34 | -20.44 | |
EV to sales | 0 | 0 | 2.21 | 0 | 0 | |
Enterprise value over EBITDA | -0.35 | -0.61 | -2.08 | -15.85 | -12.24 | |
EV to operating cash flow | -0.35 | -0.89 | -3.37 | -4.1 | -12.88 | |
EV to free cash flow | -0.35 | -0.89 | -3.37 | -4.1 | -12.88 | |
Earnings yield | -0.42 | -0.2 | -0.21 | -0.29 | -0.19 | |
Free cash flow yield | -0.43 | -0.55 | -0.15 | -0.16 | -0.07 | |
Debt to equity | 0.27 | 0.49 | -0.19 | -0.44 | -0.12 | |
Debt to assets | 0.05 | 0.05 | 0.03 | 0.04 | 0.03 | |
Net debt to EBITDA | 1.96 | 0.64 | 1.95 | 7.92 | 2.33 | |
Current ratio | 1.19 | 1.12 | 0.87 | 0.91 | 0.8 | |
Interest coverage | 75.91 | 101.45 | 15.06 | 0 | 0 | |
Income quality | 1.02 | 1.1 | 0.69 | 0.56 | 0.35 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.52 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 1.49 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0.19 | 0 | 0 | |
Graham number | 1.33 | 0.61 | 0.52 | 0.68 | 1.13 | |
ROIC | -1.44 | -1.1 | 4 | 13.68 | 1.68 | |
Return on tangible assets | -0.33 | -0.15 | -0.31 | -0.68 | -0.94 | |
Graham Net | 0.01 | -0.02 | -0.2 | -0.11 | -0.18 | |
Working capital | 9M | 3.88M | -4.19M | -4.37M | -11.02M | |
Tangible asset value | 9.63M | 4.06M | -4.07M | -4.33M | -11.04M | |
Net current asset value | 8.46M | 3.01M | -5.01M | -5.16M | -11.75M | |
Invested capital | 0.27 | 0.49 | -0.19 | -0.44 | -0.12 | |
Average receivables | 282K | 275.5K | 280K | 285K | 285K | |
Average payables | 7.83M | 5.75M | 5.04M | 5.12M | 5.35M | |
Average inventory | -138K | 2.52M | 2.52M | 3.05M | 5.67M | |
Days sales outstanding | 0 | 0 | 2.41 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 37.4 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.95 | -1.43 | 2.31 | 6.82 | 3.84 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
APLT Frequently Asked Questions
What is Applied Therapeutics, Inc. stock symbol ?
Applied Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol APLT
What is Applied Therapeutics, Inc. stock quote today ?
Applied Therapeutics, Inc. stock price is $3.11 today.
Is Applied Therapeutics, Inc. stock public?
Yes, Applied Therapeutics, Inc. is a publicly traded company.